Lechevallier E, Dussol B, Luccioni A, Thirion X, Vacher-Copomat H, Jaber K, et al. Posttransplantation acute tubular necrosis: risk factors and implications for graft survival. Am J Kidney Dis. 1998;32:984–91.
Houghton DC, English J, Bennett WM. Chronic tubulointerstitial nephritis and renal insufficiency associated with long-term “subtherapeutic” gentamicin. J Lab Clin Med. 1988;112:694–703.
Pagtalunan ME, Olson JL, Tilney NL, Meyer TW. Late consequences of acute ischemic injury to a solitary kidney. J Am Soc Nephrol. 1999;10:366–73.
Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol. 1993;122:103–11.
Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol. 2000;15:290–301.
el Nahas AM, Muchaneta-Kubara EC, Zhang G, Adam A, Goumenos D. Phenotypic modulation of renal cells during experimental and clinical renal scarring. Kidney Int. 1996;54:S23–7.
Forbes JM, Leaker B, Hewitson TD, Becker GJ, Jones CL. Macrophage and myofibroblast involvement in ischemic acute renal failure is attenuated by endothelin receptor antagonists. Kidney Int. 1999;55:198–208.
Roelofs M, Faggian L, Pampinella F, Paulon T, Franch R, Chiavegato A, et al. Transforming growth factor beta1 involvement in the conversion of fibroblasts to smooth muscle cells in the rabbit bladder serosa. Histochem J. 1998;30:393–404.
Moyses Neto M, Costa RS, Volpini RA, Garcia TM, Rodrigues FF, Coimbra TM. Interstitial alterations in renal cortex in acute tubular necrosis (ATN) post-renal transplantation and in patients with ATN not related to renal transplant. Clin Transplant. 2004;18:156–65.
Ricardo SD, van Goor H, Eddy AA. Macrophage diversity in renal injury and repair. J Clin Invest. 2008;118:3522–30.
Chadban SJ, Wu H, Hughes J. Macrophages and kidney transplantation. Semin Nephrol. 2010;30:278–89.
Weber KS, von Hundelshausen P, Clark-Lewis I, Weber PC, Weber C. Differential immobilization and hierarchical involvement of chemokines in monocyte arrest and transmigration on inflamed endothelium in shear flow. Eur J Immunol. 1999;29:700–12.
Tang WW, Qi M, Warren JS. Monocyte chemoattractant protein 1 mediates glomerular macrophage infiltration in anti-GBM Ab GN. Kidney Int. 1996;50:665–71.
Kitagawa K, Wada T, Furuichi K, Hashimoto H, Ishiwata Y, Asano M, et al. Blockade of CCR2 ameliorates progressive fibrosis in kidney. Am J Pathol. 2004;165:237–46.
Tang WW, Qi M, Warren JS, Van GY. Chemokine expression in experimental tubulointerstitial nephritis. J Immunol. 1997;159:870–6.
Wada T, Furuichi K, Sakai N, Iwata Y, Kitagawa K, Ishida Y, et al. Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. J Am Soc Nephrol. 2004;15:940–8.
Eardley KS, Zehnder D, Quinkler M, Lepenies J, Bates RL, Savage CO, et al. The relationship between albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney disease. Kidney Int. 2006;69:1189–97.
Dantas M, Romao EA, Costa RS, dos Reis MA, Vieira Neto OM, Ribeiro RA, et al. Urinary excretion of monocyte chemoattractant protein-1: a biomarker of active tubulointerstitial damage in patients with glomerulopathies. Kidney Blood Press Res. 2007;30:306–13.
Dubinski B, Boratynska M, Kopeé W, Szyber P, Patrzalek D, Klinger M. Activated cells in urine and monocyte chemotatic peptide-1 (MCP-1) - sensitive rejection markers in renal graft recipients. Transplantl Immunol. 2008;18:2003–7.
Prodjosudjadi W, Daha MR, Gerritsma JS, Florijn KW, Barendregt JN, Bruijn JA, et al. Increased urinary excetion of monocyte chemoattractant protein-1 during acute renal allograft rjection. Nephrol Dial Transplant. 1996;11:1096–103.
Sean Eardley K, Cockwell P. Macrophages and progressive tubulointerstitial disease. Kidney Int. 2005;68:437–55.
Rodriguez-Iturbe B, Pons H, Herrera-Acosta J, Johnson RJ. Role of immunocompetent cells in nonimmune renal diseases. Kidney Int. 2001;59:1626–40.
Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med. 1996;334:1448–60.
Schlondorff D. The role of chemokines in the initiation and progression of renal disease. Kidney Int. 1995;49:S44–7.
Summan M, Warren GL, Mercer RR, Chapman R, Hulderman T, Van Rooijen N, et al. Macrophages and skeletal muscle regeneration: a clodronate-containing liposome depletion study. Am J Physiol Regul Integr Comp Physiol. 2006;290:R1488–95.
Vandivier RW, Henson PM, Douglas IS. Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest. 2006;129:1673–82.
Kliem V, Johnson RJ, Alpers CE, Yoshimura A, Couser WG, Koch KM, et al. Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int. 1996;49:666–78.
Groma V. Demonstration of collagen type VI and alpha-smooth muscle actin in renal fibrotic injury in man. Nephrol Dial Transplant. 1998;13:305–12.
Eddy AA. Progression in chronic kidney disease. Adv Chronic Kidney Dis. 2005;12:353–65.
Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349:2326–33.
Pilmore HL, Painter DM, Bishop GA, McCaughan GW, Eris JM. Early up-regulation of macrophages and myofibroblasts: a new marker for development of chronic renal allograft rejection. Transplantation. 2000;69:2658–62.
McLaren AJ, Jassem W, Gray DW, Fuggle SV, Welsh KI, Morris PJ. Delayed graft function: risk factors and the relative effects of early function and acute rejection on long-term survival in cadaveric renal transplantation. Clin Transplant. 1999;13:266–72.
Ojo AO, Wolfe RA, Held PJ, Port FK, Schmouder RL. Delayed graft function: risk factors and implications for renal allograft survival. Transplantation. 1997;63:968–74.
Segerer S, Hughes E, Hudkins KL, Mack M, Goodpaster T, Alpers CE. Expression of the fractalkine receptor (CX3CR1) in human kidney diseases. Kidney Int. 2002;62:488–95.